Cryopyrin-associated periodic syndrome

Lore & Background

The syndromes within CAPS overlap clinically, and patients may have features of more than one disorder. In a retrospective cohort of 136 CAPS patients from 16 countries, the most prevalent clinical features were fever (84% of cases), skin rash (97% of cases) especially after cold exposure, and musculoskeletal involvement (86% of cases). Less common features included ophthalmological involvement (71% of cases), neurosensory hearing loss (42% of cases), neurological involvement (40% of cases), and AA amyloidosis (4% of cases). In keratoendotheliitis fugax hereditaria, systemic symptoms are not reported, but patients experience periodical transient inflammation of the corneal endothelium and stroma, leading to short-term blurring of vision and, after repeated attacks, to central corneal stromal opacities.

Reader's Guide

Cryopyrin-associated periodic syndrome is significant as a model of autoinflammatory disease driven by a single genetic pathway—gain-of-function missense mutations in NLRP3, the gene encoding cryopyrin, a major component of the interleukin 1 inflammasome. Up to 170 heterogeneous mutations have been identified, with some associated with severe phenotypes. Diagnosis is difficult due to rarity and broad presentation, requiring persistently raised inflammatory markers (C-reactive protein and serum amyloid A) plus at least two clinical symptoms, confirmed by genetic testing. Treatment targets interleukin 1β via monoclonal antibodies (canakinumab), binding proteins (rilonacept), or receptor antagonists (anakinra), which are generally effective. The condition highlights the central role of the inflammasome in systemic inflammation and the importance of targeted biologic therapies.

Did You Know?

• CAPS encompasses three syndromes—FCAS, MWS, and NOMID—that share a single genetic mutation in NLRP3.
• In a cohort of 136 CAPS patients, 97% had skin rash and 84% had fever.
• Up to 56% of CAPS patients reported a family history of the syndrome.
• Keratoendotheliitis fugax hereditaria involves a mutation in exon 1 of NLRP3, not exon 3.

Clinical Spectrum & Presentation

CAPS encompasses a range of overlapping autoinflammatory conditions affecting multiple organ systems. The three principal syndromes—familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disease (also called CINCA)—were once regarded as entirely separate diseases but in fact share a single underlying genetic pathway. A retrospective cohort of 136 patients drawn from 16 countries revealed that fever appeared in 84 percent of cases, frequently accompanied by fatigue, malaise, mood disturbances, or failure to thrive. Skin manifestations, typically urticarial or maculopapular rashes, were present in 97 percent of patients and were often triggered by cold exposure. Musculoskeletal complaints including myalgia, arthralgia, arthritis, and in more severe cases joint contracture, patellar overgrowth, or bone erosion affected 86 percent. Ophthalmological involvement such as conjunctivitis, uveitis, or optic nerve atrophy was seen in 71 percent, while neurosensory hearing loss occurred in 42 percent. Neurological features like morning headache, papilloedema, or meningitis appeared in 40 percent, and AA amyloidosis in 4 percent. Onset is typically in infancy or early childhood, with 57 percent experiencing near-daily chronic symptoms and the remaining 43 percent having only acute episodes. Up to 56 percent of patients report a family history of the condition.

Molecular Pathogenesis

The unifying genetic basis of CAPS lies in gain-of-function missense mutations in exon 3 of the NLRP3 gene, which encodes cryopyrin, a critical structural component of the interleukin-1 inflammasome. In the eye-restricted variant known as keratoendotheliitis fugax hereditaria, the responsible mutation is instead located in exon 1. Mutant cryopyrin drives aberrant, constitutive assembly of the inflammasome complex, setting in motion a cascade through caspase 1 that activates the potent pro-inflammatory cytokines interleukin-1β and interleukin-18. Activated macrophages can further release the inflammasome, amplifying the cytokine production loop. To date, up to 170 distinct NLRP3 mutations have been catalogued, and some evidence suggests that rarer mutations correlate with more severe phenotypes, while particular mutations may be linked to specific clinical presentations—likely reflecting how each variant differentially modulates inflammasome activity against an individual's broader genetic backdrop. Inheritance follows an autosomal dominant pattern with variable penetrance, meaning not every carrier will manifest the full clinical picture.

Diagnostic Challenges

Because CAPS is exceedingly rare and its clinical expression spans a wide array of organ systems, reaching a definitive diagnosis is notoriously difficult, and a substantial gap often separates the first symptoms from a confirmed identification. Clinicians have developed specific criteria to aid recognition: persistently elevated acute-phase reactants, specifically C-reactive protein and serum amyloid A, must be present alongside at least two of a defined symptom list that includes urticarial rash, cold-triggered episodes, sensorineural hearing loss, chronic aseptic meningitis, musculoskeletal complaints, or skeletal abnormalities. However, final confirmation always rests on genetic testing that identifies the responsible NLRP3 mutation. The overlap between the three syndromes within the CAPS spectrum, combined with the fact that individual patients may display features of more than one disorder simultaneously, further complicates the diagnostic picture. The broad differential and the rarity of the condition mean that many affected individuals, particularly children presenting in infancy, endure prolonged periods of uncertainty before the correct diagnosis is established.

Therapeutic Strategies

Because interleukin-1β sits at the center of CAPS pathogenesis, modern treatment is directed squarely at neutralizing this cytokine. Three principal classes of biologic agents are employed: monoclonal antibodies such as canakinumab, soluble binding proteins or traps like rilonacept, and interleukin-1 receptor antagonists including anakinra. These therapies are generally effective at alleviating the constellation of symptoms and producing substantial reductions in inflammatory markers. Beyond these established options, individual case reports have indicated that thalidomide and the anti-IL-6 receptor antibody tocilizumab may also offer benefit in certain patients. The therapeutic logic is straightforward: by interrupting the IL-1β-driven inflammatory cascade at its molecular origin, clinicians can address the systemic inflammation that manifests across skin, joints, eyes, and the central nervous system. This targeted approach represents a significant advance over earlier, less specific management strategies and has meaningfully transformed the outlook for individuals living with this rare autoinflammatory condition.